Integrated Pharmaceuticals, Inc. Announces New Product Development and Signs a License and Exclusive Supply Agreement

March 29, 2005

Integrated Pharmaceuticals, Inc. Fitchburg, MA (OTC: PK: INTP) announced today that it has developed a proprietary technology for making hot drinks healthier and more nutritious. The new technology involves a system for providing nutrients such as calcium in coffee and tea in a manner that does not noticeably affect the taste or flavor of the beverage. The Company's patent-pending technology can be applied to several other applications that will allow beverage companies to deliver healthy products to consumers at an affordable price

Integrated Pharmaceuticals (IntePharm) also announced that it has signed a non-exclusive license and an exclusive product supply agreement with a distributor for the coffee additive. The agreement permits the distributor to purchase IntePharm's coffee product and sell it under its own brand name. The agreement requires the distributor to purchase the product only from Integrated Pharmaceuticals. The distributor signed the license agreement after testing coffee product samples and completing a field application trial. To the best of IntePharm's knowledge, no other manufacturer has a similar product on the market.

The distributor has told IntePharm that it expects to purchase approximately $2.5 million of the coffee product in first year after product launch, which IntePharm expects will occur during the second quarter of 2005. IntePharm is currently finalizing arrangements for the packaging of this product, which the licensee will pay for separately. IntePharm is exploring other potential licensing opportunities for the beverage products made possible by its new technology, and hopes that this product line will be a major contributor to its growth.

"We are excited to have this licensing and sales agreement signed based on the strong intellectual property portfolio of the Company" said Dr. Chinmay Chatterjee, CEO of Integrated Pharmaceuticals. Dr. Chatterjee said further "IntePharm could achieve this progress only because of the purity of the products which are manufactured in the Fitchburg facility in MA using the Company's patented technologies". Integrated Pharmaceuticals recently commenced production at its facility in Fitchburg, Massachusetts and expects to begin shipping product in June pursuant to its previously announced five-year, $30 million supply agreement with FragChem.

About the Company

IntePharm is an emerging producer of pharmaceuticals, specialty compounds and chemicals for the pharmaceutical, nutraceutical and food industries. In addition to making products, IntePharm discovers and develops more efficient and cost-effective manufacturing processes. These processes are developed using a comprehensive technology platform that combines metabolic engineering, cellular genetics, advanced bioprocess engineering, and computer simulation science. The company owns several other pending patents for new products and technologies for immediate commercialization in food and nutritional products market.

For further information please contact Dr. Chinmay Chatterjee, Integrated Pharmaceuticals, Inc. (IntePharm), at (978) 696-0020, or visit http://www.intepharm.com.

Forward-Looking Statements

Certain statements contained in this press release that are not historical facts constitute "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in general, predict, indicate or imply future results, performance or achievements and generally use words so indicative. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company and its business to be materially different from that expressed or implied by such forward-looking statements. Included in those factors are the following: our dependence on a limited number of potential customers; limited managerial experience of our executives; possible needs for additional capital; possible delays in product development and delivery schedules; deferred or lost sales because of the complex sales process prevalent in the industries that we seek to serve; increased competitive pressure; and rapid technological changes. Forward-looking statements by their very nature are uncertain. There can be no guarantee that any forward-looking statement will be fulfilled. The Company assumes no obligation to update forward-looking statements to reflect actual results or changes in or additions to the factors affecting such forward-looking statements.

SOURCE Integrated Pharmaceuticals, Inc. Web Site: http://www.intepharm.com

Copyright © 1996-2004 PR Newswire Association LLC. All Rights Reserved. A United Business Media company.